BACKGROUND: The aim of this study was to evaluate the short- and long-term safety experience of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. METHODS: The medical records of 297 consecutive patients with CD treated with infliximab at the Beth Israel Deaconess Medical Center were reviewed for demographic features and adverse events. RESULTS: The 297 patients received a total of 1794 infusions. Patients received a median of four infusions and had a median follow-up of 14.3 months. Forty-four patients (15%) experienced a serious adverse event, requiring the infusion to be stopped in 33 patients (11%). Acute infusion reactions occurred in 18 patients (6%) including respiratory problems in 10 patients (3%) and an anaphylactoid reaction in 1 patient (0.3%). Serum sickness-like disease occurred in one patient (0.3%) and three patients (1%) developed drug-induced lupus. One patient developed a probable new demyelination disorder. Eight patients (2.7%), all of whom were on concurrent immunosuppressants, developed a serious infection, one resulting in fatal sepsis. Six patients (2%) developed malignancies including two lymphomas and two skin cancers. A total of four (1.3%) deaths were observed (median age 72.5 years); two due to gastrointestinal bleeding, one due to sepsis, and one due to malignancy. CONCLUSIONS: While short- and long-term infliximab therapy was generally well tolerated, serious adverse events occurred in 15% of patients including drug-induced lupus, fatal sepsis, and malignancy. Concomitant immunosuppressants were significantly associated with infections and deaths, particularly among elderly patients.
BACKGROUND: The aim of this study was to evaluate the short- and long-term safety experience of infliximab treatment in patients with Crohn's disease (CD) in clinical practice. METHODS: The medical records of 297 consecutive patients with CD treated with infliximab at the Beth Israel Deaconess Medical Center were reviewed for demographic features and adverse events. RESULTS: The 297 patients received a total of 1794 infusions. Patients received a median of four infusions and had a median follow-up of 14.3 months. Forty-four patients (15%) experienced a serious adverse event, requiring the infusion to be stopped in 33 patients (11%). Acute infusion reactions occurred in 18 patients (6%) including respiratory problems in 10 patients (3%) and an anaphylactoid reaction in 1 patient (0.3%). Serum sickness-like disease occurred in one patient (0.3%) and three patients (1%) developed drug-induced lupus. One patient developed a probable new demyelination disorder. Eight patients (2.7%), all of whom were on concurrent immunosuppressants, developed a serious infection, one resulting in fatal sepsis. Six patients (2%) developed malignancies including two lymphomas and two skin cancers. A total of four (1.3%) deaths were observed (median age 72.5 years); two due to gastrointestinal bleeding, one due to sepsis, and one due to malignancy. CONCLUSIONS: While short- and long-term infliximab therapy was generally well tolerated, serious adverse events occurred in 15% of patients including drug-induced lupus, fatal sepsis, and malignancy. Concomitant immunosuppressants were significantly associated with infections and deaths, particularly among elderly patients.
Authors: Victoria Rai; Cindy Traboulsi; Alexa Silfen; Max T Ackerman; Amarachi I Erondu; Jordan E Karpin; George Gulotta; David T Rubin Journal: Crohns Colitis 360 Date: 2021-08-02
Authors: Cathy Lu; Alistair Waugh; Robert J Bailey; Raeleen Cherry; Levinus A Dieleman; Leah Gramlich; Kata Matic; Mario Millan; Karen I Kroeker; Daniel Sadowski; Christopher W Teshima; Dennis Todoruk; Clarence Wong; Karen Wong; Richard N Fedorak Journal: World J Gastroenterol Date: 2012-09-28 Impact factor: 5.742
Authors: Chang Hwan Choi; In Do Song; Young Ho Kim; Ja Seol Koo; You Sun Kim; Joo Sung Kim; Nayoung Kim; Eun Soo Kim; Jae Hak Kim; Ji Won Kim; Tae Oh Kim; Hyun Soo Kim; Hyo Jong Kim; Young Sook Park; Dong Il Park; Soo Jung Park; Hyun Joo Song; Sung Jae Shin; Suk Kyun Yang; Byong Duk Ye; Kang Moon Lee; Bo In Lee; Sun Young Lee; Chang Kyun Lee; Jong Pil Im; Byung Ik Jang; Tae Joo Jeon; Yu Kyung Cho; Sae Kyung Chang; Seong Ran Jeon; Sung Ae Jung; Yoon Tae Jeen; Jae Myung Cha; Dong Soo Han; Won Ho Kim Journal: Yonsei Med J Date: 2016-11 Impact factor: 2.759